Areas where scientific evidence is lacking or incomplete.
The clinical development programme was discontinued before long-term cancer incidence data could be collected. Because IGF-1 promotes cell proliferation, the risk of accelerating undiagnosed malignancies with chronic use is pharmacologically plausible but unquantified in humans.
Implications: Users taking MK-677 for extended periods are operating entirely outside the evidence window for cancer risk. The theoretical concern is grounded in IGF-1 biology but cannot be confirmed or dismissed without longitudinal cohort data.
The CHF signal came from frail elderly patients with pre-existing cardiac vulnerability. Long-term cardiovascular effects in healthy adults aged 30-60 are unknown. No trial has assessed whether the fluid retention and cardiac preload effects accumulate meaningfully in younger populations.
Implications: The absence of evidence is not evidence of safety. The elderly CHF signal cannot be dismissed as irrelevant to younger users without specific data.
Despite frequent marketing claims, there are no human clinical trials establishing direct improvements in skin elasticity, thickness, hair quality, or nail growth from MK-677 use. The claims rest on the general GH/IGF-1 mechanism rather than compound-specific evidence.
Implications: Users seeking cosmetic benefits are relying on mechanistic inference, not clinical data. The collagen synthesis data (26% increase at 8 weeks) is from a single small study.
No human clinical trials assess MK-677 for therapeutic wound healing, tendon repair, or ligament recovery. While GH and IGF-1 are regulators of tissue repair, the compound-specific evidence does not exist.
Implications: Users taking MK-677 for injury recovery are extrapolating from GH biology, not from MK-677 data. The functional gap observed in muscle (mass without strength) raises questions about whether the tissue repair signal translates to structural quality.
Mouse studies show GH secretagogue treatment duplicates GH injection immune enhancement, increases tumour resistance, and reverses thymic involution. No human immune function data exists specifically for MK-677.
Implications: The immune claims are preclinical only. Translation from mouse to human immune function is historically unreliable. The NAFLD immunomodulation research (Th17 inhibition) may eventually provide human immune data.
Most clinical trials used 25 mg/day. Limited data exists for 10 mg (52% IGF-1 increase) and essentially none for 5 mg or 15 mg. The dose-response curve for both efficacy and side effects at lower doses is poorly characterised.
Implications: The community-standard conservative dose of 10 mg rests on a single data point. Whether lower doses maintain the sleep benefit while minimising metabolic cost is unstudied.
MK-677 causes transient prolactin elevations. The potential for prolactin-driven side effects (reduced libido, erectile dysfunction) is mentioned in sources but lacks specific clinical data exploring these outcomes.
Implications: Users reporting sexual side effects have no clinical framework to distinguish prolactin-mediated effects from other causes. Monitoring prolactin during extended use is prudent but not evidence-based for this specific compound.
Expert disagreements and competing evidence.
Marketing sources claim MK-677 leads to accelerated fat loss by increasing metabolic rate and helping the body oxidise fat more efficiently through elevated GH and IGF-1.
Mechanistic reasoning from GH lipolysis pathway and BMR increase data.
Source: Performance and wellness marketing materials
Clinical trials show no significant change in total fat mass or visceral fat despite a transient 15% BMR increase. The powerful appetite spike from ghrelin receptor activation offsets the lipolytic advantage of elevated GH.
Svensson et al. 1998 (JCEM), Nass et al. 2008 body composition data.
Source: Clinical trial body composition data
Verdict Note
The clinical data is clear: MK-677 does not reduce body fat in controlled settings. The mechanistic reasoning ignores the appetite mechanism. Fat-free mass increases, total fat mass does not decrease.
Marketing materials claim MK-677 provides increased muscle mass and strength.
General GH/IGF-1 anabolic mechanism and nitrogen retention data.
Source: Performance marketing
Multiple clinical trials, including a 2-year study in older adults, found that significant FFM gain (1.1 kg) produced no improvement in skeletal muscle strength, physical function, gait speed, or stair-climbing power.
Nass et al. 2008 (2-year RCT), Adunsky et al. 2011 (hip fracture trial).
Source: Clinical trial functional outcome data
Verdict Note
The distinction between fat-free mass and functional muscle is critical. MK-677 increases the former without increasing the latter. The lean mass is real but hollow.
One pharmacological source states MK-677 produces sustained increases in GH and IGF-1 while also raising cortisol levels.
Pharmacological evaluations noting cortisol increase.
Source: General pharmacological reviews
Other clinical sources report that MK-677 increases GH without significantly altering cortisol levels.
Detailed clinical trial cortisol measurements.
Source: Clinical trial endocrine panel data
Verdict Note
Both are partially correct. Cortisol does increase modestly and statistically significantly in elderly populations. But it remains within normal physiological range. The practical significance depends on baseline cortisol status and duration of use.
Wellness clinics state they prescribe and administer human-grade or pharmaceutical-grade ibutamoren to patients under medical supervision.
Wellness clinic marketing and service offerings.
Source: Commercial wellness clinics
Regulatory sources state MK-677 is not FDA-approved, has no approved drug substance status, and is not eligible for compounding under Section 503A or 503B.
FDA regulatory framework, 503A/503B compounding rules.
Source: FDA regulatory guidance, OPSS
Verdict Note
The regulatory position is clear: MK-677 has no approved drug substance status and no legal compounding pathway. Clinics offering it are operating outside the regulatory framework. Users should understand this distinction.
Some guides list enhanced bone recovery as a primary benefit of MK-677.
General GH/IGF-1 bone anabolism mechanism.
Source: Wellness and supplement guides
Clinical research shows MK-677 increases bone turnover markers but does not increase bone mineral density when used alone. Without an antiresorptive agent, high remodelling can transiently lower localised bone density.
Murphy et al. 2001, osteocalcin and N-telopeptide data.
Source: Clinical trial bone density data
Verdict Note
MK-677 is not a bone-building agent when used alone. The combination with alendronate (4.2% vs 2.5% BMD increase at femoral neck) shows the formation signal is real, but it requires an antiresorptive partner to translate into density.
Preclinical animal models (5XFAD mice) showed MK-677 could alleviate amyloid-beta pathology and offer neuroprotection.
5XFAD transgenic mouse model studies.
Source: Preclinical Alzheimer's research
A large-scale human trial (N=563, 12 months) found absolutely no clinical benefit in slowing Alzheimer's disease progression despite 72.9% IGF-1 increase.
Sevigny et al. 2008, Neurology. N=563, 12-month RCT.
Source: Sevigny et al. 2008
Verdict Note
The human trial definitively failed. This is a textbook example of preclinical-to-clinical translation failure. MK-677 does not protect against Alzheimer's despite raising IGF-1 to the levels that worked in mice.